利奈唑胺治疗革兰阳性菌感染的临床疗效：澳大利亚某医院的经验
Use of pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital.
机构信息
Infectious Diseases Unit, St. Vincent's Hospital, 1 Lochner St., West Hobart, Melbourne, Victoria 7000, Australia.
出版信息
Antimicrob Agents Chemother. 2010 Sep;54(9):3949-52. doi: 10.1128/AAC.00212-10. Epub 2010 Jun 14.
Abstract
Thirty-six patients were treated with pristinamycin for 46 different microbiological isolates between April 2007 and July 2009. Pathogens included 9 methicillin-resistant Staphylococcus aureus isolates, 13 methicillin-resistant coagulase negative staphylococci, and 9 vancomycin-resistant enterococci. Sites of infections included 12 osteomyelitis cases, 10 prosthetic joints, 4 other prostheses, and 1 epidural abscess. Five patients ceased treatment due to side effects. Ten patients were cured of their infections, and 21 patients had infections successfully suppressed.
摘要
36 例患者在 2007 年 4 月至 2009 年 7 月期间接受了普司他汀治疗 46 种不同的微生物分离物。病原体包括 9 株耐甲氧西林金黄色葡萄球菌分离株、13 株耐甲氧西林凝固酶阴性葡萄球菌和 9 株万古霉素耐药肠球菌。感染部位包括 12 例骨髓炎病例、10 例人工关节、4 例其他假体和 1 例硬膜外脓肿。5 例患者因副作用停止治疗。10 例患者感染治愈，21 例患者感染得到有效抑制。
相似文献
1
Use of pristinamycin for infections by gram-positive bacteria: clinical experience at an Australian hospital.利奈唑胺治疗革兰阳性菌感染的临床疗效：澳大利亚某医院的经验
Antimicrob Agents Chemother. 2010 Sep;54(9):3949-52. doi: 10.1128/AAC.00212-10. Epub 2010 Jun 14.
2
Oral pristinamycin for the treatment of resistant Gram-positive infections in patients with cancer: Evaluation of clinical outcomes.口服普那霉素治疗癌症患者耐药革兰阳性感染：临床疗效评估。
Int J Antimicrob Agents. 2016 May;47(5):391-6. doi: 10.1016/j.ijantimicag.2016.01.017. Epub 2016 Mar 12.
3
Pristinamycin as adjunctive therapy in the management of Gram-positive multi-drug resistant organism (MDRO) osteoarticular infection.普瑞米星作为革兰氏阳性多重耐药菌（MDRO）骨关节炎感染管理中的辅助治疗药物。
J Infect. 2008 Sep;57(3):191-7. doi: 10.1016/j.jinf.2008.07.002. Epub 2008 Aug 13.
4
Pristinamycin: old drug, new tricks?普那霉素：老药新用？
J Antimicrob Chemother. 2014 Sep;69(9):2319-25. doi: 10.1093/jac/dku167. Epub 2014 Jun 2.
5
Streptogramins for the treatment of infections caused by Gram-positive pathogens.用于治疗革兰氏阳性病原体引起的感染的链阳菌素类药物。
Expert Rev Anti Infect Ther. 2021 May;19(5):587-599. doi: 10.1080/14787210.2021.1834851. Epub 2020 Oct 26.
6
Bacteriologic profile and antibiogram of blood culture isolates from a children's hospital in Kabul.喀布尔一家儿童医院血培养分离株的细菌学特征及抗菌谱
J Coll Physicians Surg Pak. 2014 Jun;24(6):396-399.
7
Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.口服普里司他霉素成功治疗耐甲氧西林金黄色葡萄球菌（MRSA）和其他葡萄球菌属引起的骨关节炎感染
J Antimicrob Chemother. 2005 Jun;55(6):1008-12. doi: 10.1093/jac/dki108. Epub 2005 Apr 21.
8
National surveillance of antimicrobial resistance among Gram-positive bacteria in Saudi Arabia.沙特阿拉伯革兰氏阳性菌抗菌药物耐药性的全国监测。
J Chemother. 2014 Feb;26(1):13-8. doi: 10.1179/1973947813Y.0000000084. Epub 2013 Dec 6.
9
Antimicrobial-resistant gram-positive bacteria in PD peritonitis and the newer antibiotics used to treat them.腹膜透析相关性腹膜炎中耐抗菌药物的革兰氏阳性菌以及用于治疗它们的新型抗生素。
Perit Dial Int. 2005 Jul-Aug;25(4):313-9.
10
Novel agents for resistant Gram-positive infections--a review.用于耐药革兰氏阳性菌感染的新型药物——综述
Int J Infect Dis. 2002 Mar;6 Suppl 1:S38-46. doi: 10.1016/s1201-9712(02)90153-0.
引用本文的文献
1
Pristinamycin-antibiotic combinations against methicillin-resistant Staphylococcus aureus recovered from skin infections.针对从皮肤感染中分离出的耐甲氧西林金黄色葡萄球菌的普那霉素-抗生素联合用药
BMC Infect Dis. 2025 Sep 16;25(1):1107. doi: 10.1186/s12879-025-11433-0.
2
Natural Products That Contain Higher Homologated Amino Acids.含有高级同系氨基酸的天然产物。
Chembiochem. 2024 May 2;25(9):e202300822. doi: 10.1002/cbic.202300822. Epub 2024 Apr 9.
3
Therapeutics for Vancomycin-Resistant Enterococcal Bloodstream Infections.万古霉素耐药肠球菌血流感染的治疗方法。
Clin Microbiol Rev. 2023 Jun 21;36(2):e0005922. doi: 10.1128/cmr.00059-22. Epub 2023 Apr 17.
4
Pharmacotherapy of Lower Respiratory Tract Infections in Elderly-Focused on Antibiotics.老年人下呼吸道感染的药物治疗——以抗生素为重点
Front Pharmacol. 2019 Oct 31;10:1237. doi: 10.3389/fphar.2019.01237. eCollection 2019.
5
Correction of Linezolid-Induced Myelotoxicity After Switch to Tedizolid in a Patient Requiring Suppressive Antimicrobial Therapy for Multidrug-Resistant Prosthetic-Joint Infection.在一名因耐多药人工关节感染需要抑制性抗菌治疗的患者中，换用替地唑胺后利奈唑胺所致骨髓毒性的纠正
Open Forum Infect Dis. 2018 Sep 25;5(10):ofy246. doi: 10.1093/ofid/ofy246. eCollection 2018 Oct.
6
A new strategy to fight antimicrobial resistance: the revival of old antibiotics.对抗抗菌素耐药性的新策略：旧抗生素的复兴。
Front Microbiol. 2014 Oct 20;5:551. doi: 10.3389/fmicb.2014.00551. eCollection 2014.
7
Design-driven, multi-use research agendas to enable applied synthetic biology for global health.以设计为驱动的多用途研究议程，推动应用合成生物学服务全球健康。
Syst Synth Biol. 2013 Sep;7(3):79-86. doi: 10.1007/s11693-013-9118-2. Epub 2013 Jul 20.
8
The prevention and management of infections due to multidrug resistant organisms in haematology patients.血液学患者中多重耐药菌感染的预防与管理
Br J Clin Pharmacol. 2015 Feb;79(2):195-207. doi: 10.1111/bcp.12310.
9
Frontline antibiotic therapy.一线抗生素治疗。
Clin Med (Lond). 2013 Jun;13(3):263-8. doi: 10.7861/clinmedicine.13-3-263.
本文引用的文献
1
Linezolid: a review of safety and tolerability.利奈唑胺：安全性与耐受性综述
J Infect. 2009 Sep;59 Suppl 1:S59-74. doi: 10.1016/S0163-4453(09)60009-8.
2
Pristinamycin as adjunctive therapy in the management of Gram-positive multi-drug resistant organism (MDRO) osteoarticular infection.普瑞米星作为革兰氏阳性多重耐药菌（MDRO）骨关节炎感染管理中的辅助治疗药物。
J Infect. 2008 Sep;57(3):191-7. doi: 10.1016/j.jinf.2008.07.002. Epub 2008 Aug 13.
3
Successful oral pristinamycin therapy for osteoarticular infections due to methicillin-resistant Staphylococcus aureus (MRSA) and other Staphylococcus spp.口服普里司他霉素成功治疗耐甲氧西林金黄色葡萄球菌（MRSA）和其他葡萄球菌属引起的骨关节炎感染
J Antimicrob Chemother. 2005 Jun;55(6):1008-12. doi: 10.1093/jac/dki108. Epub 2005 Apr 21.
4
ANTIBACTERIAL ACTIVITY OF LINCOMYCIN AND PRISTINAMYCIN: A COMPARISON WITH ERYTHROMYCIN.林可霉素和普那霉素的抗菌活性：与红霉素的比较
Br Med J. 1964 Sep 5;2(5409):603-6. doi: 10.1136/bmj.2.5409.603.
5
Oral streptogramins in the management of patients with methicillin-resistant Staphylococcus aureus (MRSA) infections.
J Antimicrob Chemother. 2003 Mar;51(3):731-5. doi: 10.1093/jac/dkg143.
6
Evolution and epidemiology of MLS resistance.大环内酯类-林可酰胺类-链阳菌素抗性的进化与流行病学
J Antimicrob Chemother. 1985 Jul;16 Suppl A:137-49. doi: 10.1093/jac/16.suppl_a.137.
7
Comparative in-vitro activity of erythromycin, vancomycin and pristinamycin.红霉素、万古霉素和利奈唑胺的体外活性比较
Infection. 1988;16(6):365-70. doi: 10.1007/BF01644551.
8
Comparative in vitro activities of pristinamycin and other antimicrobial agents against genital pathogens.普那霉素与其他抗菌药物对生殖道病原体的体外活性比较
Antimicrob Agents Chemother. 1989 Dec;33(12):2152-4. doi: 10.1128/AAC.33.12.2152.
9
In-vitro activity of RP 59500, a new semisynthetic streptogramin antibiotic, against gram-positive bacteria.
J Antimicrob Chemother. 1992 Jul;30 Suppl A:29-37. doi: 10.1093/jac/30.suppl_a.29.
Zotero 插件